Merck and AstraZeneca get Lynparza OK in China for new indication; BARDA exercises first option with Marinus
AstraZeneca and Merck’s Lynparza is approved in China for yet another indication.
Chinese regulators approved the blockbuster cancer drug and PARP inhibitor as a first-line maintenance treatment for adults in several specific circumstances: with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to first-line platinum-based chemotherapy in combination with Avastin, and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.